Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed primary or metastatic malignancy, including any of the following:
• •* Colorectal cancer
• •* Hepatocellular cancer
• •* Pancreatic exocrine cancer
• •* Pancreatic endocrine cancer
• •* Breast cancer
• •* Melanoma
• •* Sarcoma
• •* Primary adrenal tumors
• •* Renal cell carcinoma
• •* Ovarian cancer
• •* Adenocarcinoma of gastrointestinal origin
• •* Peritoneal mesothelioma
• •Clinical indication for surgical resection
• •No known brain metastases
• •* Previously treated brain metastases with no evidence of recurrence allowed
• •Hormone receptor status not specified
• •PATIENT CHARACTERISTICS:
• •Male or female
• •Menopausal status not specified
• •ECOG performance status 0-2
• •Life expectancy ≥ 5 months
• •Absolute neutrophil count ≥ 1,500/mm³
• •Platelet count ≥ 100,000/mm³
• •Creatinine ≤ 2.0 mg/dL
• •Bilirubin ≤ 2.5 mg/dL
• •ALT and AST ≤ 3 times upper limit of normal (ULN)
• •Alkaline phosphatase ≤ 3 times ULN
• •Hemoglobin ≥ 9.0 g/dL
• •Ejection fraction ≥ 45% by echocardiogram, thallium stress test, or MUGA (for patients with prior cardiovascular disease)
• •FEV\_1 OR DLCO \> 30% of predicted (for patients with prior pulmonary disease)
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No active bacterial infection
• •* Localized chronic infection (e.g., mild acne, tinea pedis) allowed
• •No known bleeding disorder
• •No other serious illness including, but not limited to, any of the following:
• •* Unstable angina
• •* Severe oxygen-dependent chronic obstructive pulmonary disease
• •* End-stage liver disease
• •No HIV positivity
• •PRIOR CONCURRENT THERAPY:
• •Recovered from prior therapy, including cytotoxic drugs, radiotherapy, surgery, or other anticancer modalities
• •More than 3 weeks since prior biologic therapy or cytotoxic agents (6 weeks for nitrosoureas) and recovered
• •No concurrent treatment in a protocol for which patient is being evaluated for response
• •No other concurrent anticancer treatment